TECHNOLOGY PLATFORMS Archives - Page 2 of 40

KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...

Fully Automated HTS Platform for Screening Diverse Targets

High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates....

Unleashing the Power of Spectral Shift Technology

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...

HTS Platform to Advance Molecular Glue Discovery

Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...

Screening Strategies for Molecular Glue Discovery

Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...

Webinar: Target Deconvolution and Tractability Assessment

Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug discovery and target identification. By using...

mRNA Drugs: Progress, Production, and Prospects

Introduction: RNA-based therapies are a frontier in biomedicine, with the potential to fundamentally change treatments for a wide range of...

Therapeutics for Alzheimer’s Using Antidiabetic Drugs

Evidence suggests that type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction and an increased risk of developing neurocognitive...

Radionuclide Drug Conjugates in Anticancer Treatment

Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...

Knowledge Library